This toolbox provides a summary in tabular form of the various metabolic changes that may be caused by atypical antipsychotics. Included here are: average changes in weight both short and long term (Table 1), average change in lipids short term (Table 2), average change in lipids long term (Table 3), average changes in fasting glucose short and long term (Table 4), and a ranking of the propensity of the atypical antipsychotics to cause metabolic changes (Table 5).

Table 1. Effect of atypical antipsychotics on weight in adult patients with schizophrenia or bipolar disorder in short and long-term placebo-controlled trials as reported in manufacturer prescribing information.^1–10

View Fullscreen

Table 2. Effect of atypical antipsychotics on lipid profile in patients with schizophrenia or bipolar disorder in short-term (≤12 weeks), placebo controlled trials as reported in manufacturer prescribing information.^1–10

View Fullscreen

Table 3. Effect of atypical antipsychotics on lipid profile in patients with schizophrenia or bipolar disorder in long-term (≥24 weeks), placebo controlled trials as reported in manufacturer prescribing information.^1–10

View Fullscreen

Table 4. Effect of atypical antipsychotics on blood glucose and rate of fasting blood glucose elevations in patients with schizophrenia or bipolar disorder in short and long-term placebo-controlled trials as reported in manufacturer prescribing information.^1–10

View Fullscreen

Table 5. Summary of potential for metabolic adverse effects with atypical antipsychotics.^1–13

View Fullscreen